INmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 6.3% in March

INmune Bio, Inc. (NASDAQ:INMB) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,530,000 shares, a growth of 6.3% from the March 15th total of 1,440,000 shares. Approximately 13.0% of the shares of the company are sold short. Based on an average trading volume of 86,500 shares, the short-interest ratio is presently 17.7 days.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new position in shares of INmune Bio in the third quarter valued at about $25,000. Bank of America Corp DE lifted its holdings in INmune Bio by 152.1% in the 1st quarter. Bank of America Corp DE now owns 4,717 shares of the company’s stock worth $30,000 after purchasing an additional 2,846 shares in the last quarter. Advisor Group Holdings Inc. boosted its stake in INmune Bio by 52.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 9,250 shares of the company’s stock worth $59,000 after purchasing an additional 3,200 shares during the period. LPL Financial LLC bought a new stake in shares of INmune Bio during the third quarter valued at approximately $68,000. Finally, Squarepoint Ops LLC bought a new position in shares of INmune Bio during the first quarter worth $84,000. Institutional investors own 12.72% of the company’s stock.

INmune Bio Stock Down 4.5 %

Shares of NASDAQ:INMB opened at $9.15 on Wednesday. The firm’s 50 day simple moving average is $11.89 and its two-hundred day simple moving average is $10.26. INmune Bio has a 1-year low of $6.50 and a 1-year high of $14.74.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression.